

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5530732

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
BO LIANG	05/14/2019
JOHN J. BALDWIN	05/17/2019
GANG WEI	05/15/2019
RECEIVING PARTY DATA	
Name:	IVIEW THERAPEUTICS, INC.
Street Address:	108 WEST 13TH STREET
City:	WILMINGTON
State/Country:	DELAWARE
Postal Code:	19801
PROPERTY NUMBERS Total: 1	
Property Type	Number
PCT Number:	US2016058722
CORRESPONDENCE DATA	
Fax Number:	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	3127749465
Email:	rao@venturepartnerllc.com
Correspondent Name:	VENTURE PARTNER, LLC.
Address Line 1:	401 N MICHIGAN AVE.
Address Line 2:	SUITE 1200
Address Line 4:	CHICAGO, ILLINOIS 60611
ATTORNEY DOCKET NUMBER:	146660-011100
NAME OF SUBMITTER:	WEISUN RAO
SIGNATURE:	/Weisun Rao/
DATE SIGNED:	05/20/2019
Total Attachments: 2	
source=Executed Assignment (Prov. PCT and US)#page1.tif	
source=Executed Assignment (Prov. PCT and US)#page2.tif	

ASSIGNMENT

We, **Bo LIANG**, a U.S. citizen, **John J. BALDWIN**, a U.S. citizen, and **Gang WEI**, a Chinese citizen, for good and valuable consideration, receipt of which is hereby acknowledged, have assigned, sold and transferred to, and do hereby assign, sell and transfer to the following entity:

IVIEW Therapeutics, Inc., a company organized and existing under U.S. laws, with an address of 108 West 13th Street, Wilmington, Delaware 19801; its respective successor(s) and assign(s), all hereinafter referred to as the "ASSIGNEE";

(1) our entire right, title and interest in the United States and in all other countries throughout the world in and to any and all of our inventions and discoveries disclosed in:

(a) the provisional United States Application entitled "NOVEL EXTENDED RELEASE POVIDONE-IODINE OPHTHALMIC COMPOSITIONS," and filed in the United States Patent and Trademark Office on October 25, 2015, with the Application Number 62/246,073; and

(b) the International Patent Application entitled "PHARMACEUTICAL FORMULATIONS THAT FORM GEL IN SITU" and filed under the Patent Cooperation Treaty in the United States Receiving Office on October 25, 2016, with the Application No. **PCT/US2016/058722** and designating all countries, including any applications claiming priority thereto or based thereon (including national and regional phase applications based thereon), and any substitute applications therefrom; and

(c) the application for United States Letters Patent entitled "PHARMACEUTICAL FORMULATIONS THAT FORM GEL IN SITU" and filed with the United States Patent and Trademark Office on October 31, 2016, with the Application Number 15/307,989, including any renewals, revivals, reissues, reexaminations, extensions, continuations, and divisionals thereof, and any substitute applications therefrom;

(2) our full and complete right to file patent applications in the names of the ASSIGNEE, their designees, or at the election of the ASSIGNEE or their designees, on the aforesaid inventions, discoveries and applications in the United States and in any other country of the world;

(3) our entire right, title and interest in and to any Letters Patent which may issue thereon in the United States, and in all other countries of the world, and in and to any renewals, revivals, reissues, reexaminations, extensions, continuations and divisions thereof; and

(4) our entire right, title and interest in and to all Convention and Treaty Rights of all kinds thereon, including without limitation all rights of priority in any country of the world, in and to the above inventions, discoveries and applications, and all rights of priority in any country of the world deriving from the above-identified patent applications.


We hereby agree that prior to the filing of the any of the above-identified patent applications, all of our rights, title and interest in and to any and all of the above-identified applications were vested in the ASSIGNEE.


We hereby authorize and request the competent authorities to grant and to issue any and all such Letters Patent in the United States, and throughout the world to the ASSIGNEE of the entire right, title and interest therein, as fully and entirely as the same would have been held and enjoyed by me had this assignment, sale and transfer not been made.


We agree, at any time, upon the request of the ASSIGNEE to execute and to deliver to the ASSIGNEE any additional applications for patents for said inventions and discoveries, or any part or parts thereof, and any applications for patents of confirmation, registration and importation based on any Letters Patent issuing on said inventions, discoveries or applications, and divisionals, continuations, renewals, revivals, reissues, reexaminations and extensions thereof.

We further agree at any time to execute and to deliver upon request of the ASSIGNEE such additional documents, if any, as are necessary or desirable to secure patent protection on said inventions, discoveries and applications throughout all countries of the world, and otherwise to do the necessary to give full effect to and to perfect the rights of the ASSIGNEE under this Assignment, including the execution, delivery and procurement of any and all further documents evidencing this assignment, transfer and sale as may be necessary or desirable.


Agreed and Accepted by Assignors:


_____/s/ Date: 05/14/19
Bo LIANG


_____/s/ Date: 05/17/19
John J. BALDWIN


_____/s/ Date: 05/15/19
Gang WEI

Acknowledged by Assignee (IVIEW Therapeutics, Inc.):


_____/s/ Date: 05/14/19
By: Bo Liang
Its: Director